Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
92
K
Drugs & Biologics
46
K
Targets
994
K
Organizations
935
K
/
203
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
Global New Drug Research and Development Progress Weekly Report(7.1-7.7)
Drug Highlight
10 min read
Global New Drug Research and Development Progress Weekly Report(7.1-7.7)
8 July 2024
7.1-7.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
Is Pralsetinib approved by the FDA?
Drug Insights
3 min read
Is Pralsetinib approved by the FDA?
5 July 2024
Approved on September 4, 2020, pralsetinib (Gavreto) represents a significant advancement in targeted cancer therapy.
Read →
What are the prospects for the AOC therapy that boosted Avidity by 33%?
Hot Spotlight
10 min read
What are the prospects for the AOC therapy that boosted Avidity by 33%?
5 July 2024
Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.
Read →
Check out our latest report
Global Drug R&D Express (Apr 2024)

Global Drug R&D Express (Apr 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of April totaling 90 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Mar 2024)

Global Drug R&D Express (Mar 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 93 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Feb 2024)

Global Drug R&D Express (Feb 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 59 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.